Last Updated : August 14, 2024
Details
Generic Name:
omaveloxolone
Project Status:
Pending
Therapeutic Area:
Friedrich’s ataxia
Manufacturer:
Biogen Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0864-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of Friedrich’s ataxia (FA) in adults and adolescents aged 16 years and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of Friedrich’s ataxia (FA) in adults and adolescents aged 16 years and older.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 14, 2024